Zoster (Shingrix) Vaccine
Herpes Zoster (Shingles) · Postherpetic Neuralgia (PHN) · Zoster ophthalmicus · Zoster-related stroke
The same varicella-zoster virus (VZV) that causes childhood chickenpox lies dormant in nerve ganglia for life. As cellular immunity declines with age, the virus reactivates as shingles — a painful, blistering rash along a nerve dermatome. 1 in 3 Americans will develop shingles in their lifetime. Postherpetic neuralgia (PHN), a burning neuropathic pain lasting months to years, is the most feared complication.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
The same varicella-zoster virus (VZV) that causes childhood chickenpox lies dormant in nerve ganglia for life. As cellular immunity declines with age, the virus reactivates as shingles — a painful, blistering rash along a nerve dermatome. 1 in 3 Americans will develop shingles in their lifetime. Postherpetic neuralgia (PHN), a burning neuropathic pain lasting months to years, is the most feared complication.
Shingles rash causes severe burning and stabbing pain. PHN affects 10–15% of patients over 60 and can be completely debilitating — constant, severe neuropathic pain that interferes with sleep, concentration, and daily function for months or years. Older patients describe PHN as among the most severe chronic pain experiences. Zoster ophthalmicus can cause vision loss.
🛡️ Vaccine Effectiveness
Shingrix maintains >85% effectiveness through 7 years of follow-up — substantially more durable than the older Zostavax vaccine (which waned to <40% after 5–6 years). Protection expected to last at least 10 years based on current data. Immune response declines more slowly because Shingrix uses an AS01B adjuvant that generates strong CD4+ T-cell responses.
Breakthrough shingles after Shingrix is uncommon and typically milder. PHN risk is substantially reduced even in breakthrough cases.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Previously vaccinated with Zostavax: give Shingrix at least 2 months after. Immunocompromised individuals 19+: may receive Shingrix. Non-live vaccine — can be given to immunocompromised patients (unlike older Zostavax live vaccine).
⚖️ Benefits vs. Considerations
✓ Benefits
- 91% effective against shingles — among the highest VE of any adult vaccine
- Prevents postherpetic neuralgia — one of the most debilitating chronic pain conditions
- Durable protection: >85% efficacy through 7 years, expected to last 10+ years
- Non-live vaccine: can be used in immunocompromised patients (unlike old Zostavax)
- Prevents vision-threatening zoster ophthalmicus
- Medicare covers both doses for adults 50+
↕ Considerations
- Most reactogenic approved vaccine: 78% arm pain, 57% fatigue/myalgia, 17% grade 3 reactions
- Many patients take the day after dose 2 off work due to symptoms
- Requires 2 doses 2–6 months apart
- Limited post-licensure data beyond 7 years
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Shingrix has the highest rate of grade 3 (severe, activity-limiting) systemic reactions of any approved vaccine — approximately 17% of recipients. While these reactions are transient (1–3 days), some researchers and geriatric medicine specialists have raised concerns about this reactogenicity profile in frail older adults who may be particularly distressed by a day or two of significant illness (Harbecke et al., 2017).
- The economic case for vaccinating all adults from age 50 vs. age 60 or 65 is not fully settled — modeling studies differ on when the cost per QALY saved crosses standard thresholds, and some health economists argue resources are better used targeting the 70+ group where PHN risk is highest (Szabo et al., 2019).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Long-term duration of protection beyond 10 years — modeling suggests ongoing protection but real-world data limited
- Whether vaccination is cost-effective in adults under 60 — not currently recommended for this age group
- Optimal timing for immunocompromised patients — immune response may be blunted, optimal strategy not fully established
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.